Kynam Capital Management, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Kynam Capital Management, LP reported 32 stock positions worth $1.8 billion. Its top holding was Celldex Therapeutics (CLDX) at 10.9% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 9.7%) and Vaxcyte (PCVX, 9.4%). Compared with Q1 2026, it opened 4 new positions, sold out of 8, added to 12 and reduced 7. The biggest buy was Viridian Therapeutics (VRDN, shares +176%) and the biggest sale an exit from Kalvista Pharmaceuticals (KALV).
- Most Recent 13F
- Q2 2026
- Location
- PRINCETON, NJ
- CIK
- 0001907884
- Portfolio Value
- $1.8B (Q2 2026)
- SEC Filing
- 0001907884-26-000012 ↗ filed Aug 14, 2026
Holdings Value
Holdings 32 stocks · $1.8B
| CLDX Celldex Therapeutics Inc. | 10.95% | 5,322,908 | $198.1M | Reduce -8.9% |
| SNDX Syndax Pharmaceuticals Inc. | 9.73% | 8,050,959 | $176.0M | No change |
| PCVX Vaxcyte Inc. | 9.39% | 2,922,335 | $169.9M | No change |
| COGT Cogent Biosciences Inc. | 7.84% | 3,667,097 | $141.9M | Reduce -9.2% |
| VERA Vera Therapeutics Inc. | 6.85% | 2,890,059 | $124.0M | Reduce -14.9% |
| VRDN Viridian Therapeutics Inc. | 6.55% | 6,453,877 | $118.6M | Add +175.6% |
| TVTX Travere Therapeutics Inc. | 6.28% | 2,000,000 | $113.6M | Add +27.5% |
| BEAM Beam Therapeutics Inc. | 5.39% | 2,840,792 | $97.5M | Reduce -22.9% |
| URGN Urogen Pharma Ltd. | 4.95% | 2,434,207 | $89.6M | Add +8.3% |
| LEGN Legend Biotech Corp.-ADR | 4.79% | 3,001,205 | $86.7M | Add +90.4% |
| CTMX Cytomx Therapeutics Inc. | 4.50% | 21,703,093 | $81.4M | Add +44.6% |
| RLAY Relay Therapeutics Inc. | 3.41% | 3,300,000 | $61.7M | Add +131.7% |
| CGEM Cullinan Therapeutics Inc. | 3.13% | 3,114,132 | $56.7M | No change |
| MBX MBX Biosciences Inc. | 2.85% | 934,799 | $51.6M | No change |
| IMCR Immunocore Holdings PLC-ADR | 2.41% | 1,375,000 | $43.7M | Add +55.4% |
| NRIX Nurix Therapeutics Inc. | 1.60% | 1,194,757 | $29.0M | No change |
| STRO Sutro Biopharma Inc. | 1.60% | 872,558 | $29.0M | No change |
| BCRX Biocryst Pharmaceuticals Inc. | 1.39% | 2,522,660 | $25.2M | Reduce -55.6% |
| PHVS Pharvaris NV | 1.26% | 661,795 | $22.9M | Add +3.3% |
| SMMT Summit Therapeutics Inc. | 0.97% | 1,200,000 | $17.5M | New |
| PRLD Prelude Therapeutics Inc. | 0.71% | 2,415,087 | $12.9M | Add +51.6% |
| INSM Insmed Inc. | 0.59% | 100,000 | $10.7M | New |
| BNR Burning Rock Biotech Ltd.-ADR | 0.58% | 1,238,563 | $10.5M | Add +0.9% |
| GERN Geron Corp. | 0.48% | 6,836,318 | $8.8M | No change |
| AMRN Amarin Corp. PLC -ADR | 0.47% | 532,982 | $8.5M | Add +12.8% |
| ALEC Alector Inc. | 0.42% | 3,808,494 | $7.7M | Add +90.4% |
| PBLS Parabilis Medicines Inc. | 0.38% | 250,000 | $6.8M | New |
| CRBU Caribou Biosciences Inc. | 0.24% | 2,503,302 | $4.4M | No change |
| PRQR Proqr Therapeutics NV | 0.16% | 1,566,317 | $2.9M | No change |
| CADL Candel Therapeutics Inc. | 0.06% | 96,741 | $996K | Reduce -51.6% |
| ENGN Engene Therapeutics Inc. | 0.04% | 457,855 | $792K | Reduce -66.3% |
| TRAW Traws Pharma Inc. | 0.00% | 84,400 | $71K | New |
Portfolio Sells Q1 2026 → Q2 2026
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −2.33 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −2.11 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -55.6% | 1.39% | −2.04 |
| COGT Cogent Biosciences Inc. | Reduce -9.2% | 7.84% | −2.02 |
| VERA Vera Therapeutics Inc. | Reduce -14.9% | 6.85% | −1.82 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −1.19 |
| EVMN Evommune Inc. | Sold out | 0.00% | −0.91 |
| CLDX Celldex Therapeutics Inc. | Reduce -8.9% | 10.95% | −0.81 |
| ENGN Engene Therapeutics Inc. | Reduce -66.3% | 0.04% | −0.54 |
| DSGN Design Therapeutics Inc. | Sold out | 0.00% | −0.53 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −0.44 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.44 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −0.38 |
| BEAM Beam Therapeutics Inc. | Reduce -22.9% | 5.39% | −0.18 |
| CADL Candel Therapeutics Inc. | Reduce -51.6% | 0.06% | −0.01 |
Portfolio Buys Q1 2026 → Q2 2026
| VRDN Viridian Therapeutics Inc. | Add +175.6% | 6.55% | +3.65 |
| TVTX Travere Therapeutics Inc. | Add +27.5% | 6.28% | +3.32 |
| LEGN Legend Biotech Corp.-ADR | Add +90.4% | 4.79% | +2.98 |
| RLAY Relay Therapeutics Inc. | Add +131.7% | 3.41% | +2.51 |
| URGN Urogen Pharma Ltd. | Add +8.3% | 4.95% | +2.39 |
| SMMT Summit Therapeutics Inc. | New | 0.97% | +0.97 |
| IMCR Immunocore Holdings PLC-ADR | Add +55.4% | 2.41% | +0.72 |
| INSM Insmed Inc. | New | 0.59% | +0.59 |
| PBLS Parabilis Medicines Inc. | New | 0.38% | +0.38 |
| PRLD Prelude Therapeutics Inc. | Add +51.6% | 0.71% | +0.37 |
| ALEC Alector Inc. | Add +90.4% | 0.42% | +0.15 |
| PHVS Pharvaris NV | Add +3.3% | 1.26% | +0.12 |
| AMRN Amarin Corp. PLC -ADR | Add +12.8% | 0.47% | +0.04 |
| CTMX Cytomx Therapeutics Inc. | Add +44.6% | 4.50% | +0.02 |
| TRAW Traws Pharma Inc. | New | 0.00% | +0.00 |
| BNR Burning Rock Biotech Ltd.-ADR | Add +0.9% | 0.58% | −0.67 |
Options Activity Q1 2026 → Q2 2026
| TVTX Travere Therapeutics Inc. | call | Sold out | 800,000 | $23.8Mbefore exit |
| RVMD Revolution Medicines Inc. | put | Sold out | 207,500 | $20.2Mbefore exit |
| TVTX Travere Therapeutics Inc. | put | Sold out | 54,900 | $1.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $1.8B | CLDX, SNDX, PCVX, COGT, VERA |
| Q1 2026 | 36 | $1.6B | SNDX, CLDX, PCVX, COGT, VERA |
| Q4 2025 | 35 | $1.5B | COGT, VERA, SNDX, CLDX, PCVX |
| Q3 2025 | 35 | $1.3B | CLDX, SNDX, VERA, COGT, PCVX |
| Q2 2025 | 31 | $928.8M | CLDX, PCVX, VERA, SNDX, BCRX |
| Q1 2025 | 31 | $1.2B | NTRA, PCVX, CLDX, SNDX, BCRX |
| Q4 2024 | 29 | $1.5B | NTRA, PCVX, CLDX, SNDX, DVAX |
| Q3 2024 | 24 | $1.3B | NTRA, PCVX, CLDX, SNDX, COGT |
| Q2 2024 | 22 | $955.2M | NTRA, CLDX, SNDX, DVAX, COGT |
| Q1 2024 | 21 | $898.9M | NTRA, SNDX, CLDX, VERA, COGT |